Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12802969 | 0.94 | NAMPT (0.48) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL12597695 | 0.92 | NAMPT (0.49) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL12133253 | 0.91 | NAMPT (0.50) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL12133342 | 0.89 | NAMPT (0.49) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL12132990 | 0.89 | NAMPT (0.49) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL2281584 | 0.89 | NAMPT (0.49) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL12133494 | 0.89 | GRM2 (0.46) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL1349877 | 0.89 | GRM2 (0.46) | NAMPTHDAC1GRM2AKT1L3MBTL1 | |
| SCHEMBL12133211 | 0.88 | NAMPT (0.48) | NAMPTHDAC1GRM2AKT1CKS1B | |
| SCHEMBL12133395 | 0.88 | NAMPT (0.48) | NAMPTHDAC1GRM2AKT1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | NAMPT 844/4885HDAC1 329/4885GRM2 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.